BCRX Biocryst Pharmaceuticals Inc.
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
- 0 P/E
- 53.01 P/S
- 10.52 P/B
- -0.638 EPS
- -118.77% Cash ROIC
- 2.49 Cash Ratio
- 0 / 0% Dividend
- 1.28M Avg. Vol.
- 55.22M Shares
- 968.7M Market Cap.
BioCryst Pharmaceuticals, Inc. designs, optimizes, and develops small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer, and inflammatory diseases. It uses structure-based drug design, which incorporates multiple scientific disciplines, including biology, crystallography, medicinal chemistry, and computer modeling to develop new therapeutic candidates. The com...
Bidness ETC - 7 hours ago
BioCryst Receives Additional NIAID Funding to Conduct a Non-Human Primate ... - Wall Street Journal
MarketWatch - Aug 25, 2014
ETF Daily News (blog) - Aug 5, 2014
Stocks On the Move: BioCryst Pharmaceuticals, Inc., ITT Educational Services ... - Schaeffers Research (blog)
Wall Street Pit - Aug 8, 2014
Friday's Hot Stocks: Mercadolibre Inc (MELI), BioCryst Pharmaceuticals, Inc ... - Investor Wired
24/7 Wall St. - Aug 4, 2014
Ebola Drug by Tekmira May Be Used on Infected Patients - Bloomberg
Market News Call - Aug 29, 2014
Intercooler - Aug 29, 2014
Stocks in News: Google Inc (NASDAQ:GOOGL), 22nd Century Group Inc ... - Financial Wired (registration)
Wall Street Pit - Aug 13, 2014
BioCryst Receives Additional NIAID Funding to Advance Development of ... - CNNMoney
WKRB News - Aug 22, 2014
Techsonian (press release) - Aug 25, 2014